News | September 29, 2010

Implantable Cardiac Monitor Detects Asymptomatic Arrhythmias


September 29, 2010 – A prospective study found that an implantable cardiac monitor detected arrhythmias in patients who had suffered a heart attack.

The CARISMA study, which looked at Medtronic’s Reveal Plus monitor, found that it recorded arrhythmias in 46 percent of patients with ejection fractions less than or equal to 40 percent and who had previously suffered an acute myocardial infarction (AMI). Nearly 86 percent of the arrhythmias detected were asymptomatic.

The study is the first to investigate the incidence and prognostic significance of arrhythmias documented by an insertable cardiac monitor in this patient population. Results were published in Circulation.

“For the first time there are data showing that continuous long-term monitoring allows detailed insight into post-AMI arrhythmias,” said Poul Erik Bloch Thomsen, M.D., the principal investigator, Gentofte University Hospital, Copenhagen, Denmark. “Additional information about post-AMI patients can help physicians determine appropriate medical intervention, such as an implantable cardioverter-defibrillator, pacemaker, or modified drug therapy.”

Pinpointing the frequency of arrhythmias in post-AMI patients has been limited due to a lack of clinically validated measurement tools.

Of the patients diagnosed with cardiac arrhythmias, 27 percent experienced new onset atrial fibrillation, 9.8 percent had high-degree atrioventricular (AV) block, 6.7 percent had sinus bradycardia, and 13 percent had non-sustained ventricular tachycardia. Additionally, 56 patients received an implantable cardioverter-defibrillator (11 for secondary indications; 45 for primary indications) and 15 patients received a pacemaker.

For more information: www.medtronic.com


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now